This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oncothyreon Announces Data For L-BLP25 And PX-866 To Be Presented At American Society Of Clinical Oncology Meeting

Stocks in this article: ONTY

SEATTLE, May 16, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that the following presentations of data for L-BLP25 (formerly known as Stimuvax) and PX-866 will take place at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago:

Abstract #7500 START - A Phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. Charles A. Butts, MD, FRCPC Oral Abstract Session - Lung Cancer Tuesday, June 4 9:45 AM - 10:00 AM

Abstract #2053 Phase II study of PX-866 in recurrent glioblastoma. Marshall W. Pitz, MD, FRCPC General Poster Session - CNS tumors Saturday, June 1 8:00 AM - 11:45 AM

Abstract #5042 NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC). Sebastien J. Hotte, MD, MSc General Poster Session - Genitourinary Cancer Monday June 3 8:00 AM - 11:45 AM

L-BLP25 - In connection with the upcoming presentation, Oncothyreon today announced detailed results from the randomized Phase III START trial of the investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). The trial was conducted by Merck Serono, a division of Merck KGaA, Darmstadt, Germany, under a license agreement with Oncothyreon. The primary endpoint of improving overall survival (OS) was not met. In a predefined subgroup of patients receiving initial concurrent chemoradiotherapy (CRT), a combination of chemotherapy and radiotherapy given at the same time, a median overall survival of 30.8 months versus 20.6 months was observed based on a post hoc analysis in patients treated with L-BLP25 versus placebo respectively (HR 0.78, 95% CI 0.64-0.95, p=0.016, n=806).

The START trial is assessing the safety, efficacy and tolerability of L-BLP25 in patients with unresectable, locally advanced Stage III NSCLC who have not progressed after initial CRT, which is the current standard of care. Before receiving treatment with either L-BLP25 or placebo in the START trial, two-thirds of patients had received concurrent CRT and one-third had received sequential CRT (radiotherapy started after completion of chemotherapy). The trial did not meet its primary objective of demonstrating a significantly improved OS with L-BLP25 compared to placebo in the primary analysis study population (n=1,239). Median OS was 25.6 months for patients in the L-BLP25 group compared with 22.3 months for those in the placebo group (adjusted HR 0.88, 95% CI 0.75-1.03, p=0.123). In a post hoc analysis of the predefined subgroup of patients receiving initial concurrent CRT (n=806), patients receiving L-BLP25 had a median OS of 30.8 months compared to patients receiving placebo, who had a median OS of 20.6 months [HR 0.78; 95% CI 0.64-0.95; p=0.016]). In patients receiving sequential CRT followed by L-BLP25 or placebo a median OS of 19.4 months was observed for the L-BLP25 group compared with 24.6 months for the placebo group (n=433; HR 1.12; 95% CI 0.87-1.44; p=0.38). Predefined subgroup analyses included, among others, disease stage (IIIA or IIIB), response to initial CRT (stable disease versus objective response), type of initial CRT (concurrent versus sequential) and geographic region.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs